Pharmaceuticals

Global Checkpoint Inhibitor Refractory Cancer Market Projected to Expand at 11.5% CAGR by 2029

November 20, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Larger Is The Checkpoint Inhibitor Refractory Cancer Market Expected To Become By 2029 Compared With Its 2025 Level?

The market for checkpoint inhibitor refractory cancer has experienced rapid expansion in recent years. Its value is projected to rise from $32.81 billion in 2024 to $36.69 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 11.8%. Historically, this expansion can be linked to factors such as the rising incidence of cancer, heightened understanding of checkpoint inhibitors, broader cancer screening initiatives, intensified clinical trial operations, and a greater need for individualized therapies.

The checkpoint inhibitor refractory cancer market is projected to experience swift expansion over the coming years. This market is anticipated to reach a valuation of $56.64 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 11.5%. The predicted growth during this period stems from factors such as an increasing number of diagnoses, a heightened demand for personalized medicine, broader applications for checkpoint inhibitors, a growing elderly demographic, and the amplified use of biomarkers for patient selection. Key trends projected for the forecast period encompass progress in combination therapies, the emergence of next-generation checkpoint inhibitors, the incorporation of artificial intelligence (AI) into treatment strategies, the introduction of oral checkpoint inhibitors, and the creation of personalized cancer vaccines.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27251&type=smp

What Are The Key Drivers Of Growth In The Checkpoint Inhibitor Refractory Cancer Market?

The increasing occurrence of cancer is projected to stimulate the expansion of the checkpoint inhibitor refractory cancer market going forward. Cancer is defined as an ailment marked by the unrestricted division and proliferation of aberrant cells within the body. This upward trend in cancer incidence primarily stems from an aging demographic, given that extended life expectancy raises the probability of developing cancer over time. Identifying checkpoint inhibitor refractory cancer holds significance in managing the disease, as it allows for prompt detection of treatment resistance, thereby guiding medical professionals to swiftly adjust therapy and explore alternative methods that could improve patient outcomes. As an illustration, the United Nations, a US-based intergovernmental organization, reported in February 2025 that approximately 2.3 million new breast cancer cases were identified in 2022, leading to 670,000 fatalities, with global forecasts predicting a 38% surge in cases and a 68% jump in yearly deaths by 2050. Consequently, the escalating occurrence of cancer is fueling the expansion of the checkpoint inhibitor refractory cancer market.

Which Key Segments Fueling The Checkpoint Inhibitor Refractory Cancer Market?

The checkpoint inhibitor refractory cancer market covered in this report is segmented

1) By Therapy: Immune Checkpoint Inhibitors, Combination Therapies, Targeted Therapies

2) By Cancer Type: Non-Small Cell Lung Cancer (NSCLC), Melanoma, Renal Cell Carcinoma (RCC), Head And Neck Squamous Cell Carcinoma (HNSCC), Urothelial Carcinoma, Triple-Negative Breast Cancer (TNBC), Colorectal Cancer, Other Cancer Types

3) By Mechanism Of Action: Programmed Cell Death Protein (PD)-1 Inhibitors, Programmed Death-Ligand (PD)-L1 Inhibitors, Cytotoxic T-Lymphocyte–Associated Protein (CTLA)-4 Inhibitors, Other Mechanism Of Actions

4) By Administration Route: Intravenous (IV), Oral

5) By End-User: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Immune Checkpoint Inhibitors (ICIs): PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors

2) By Combination Therapies: Checkpoint Inhibitor + Chemotherapy, Checkpoint Inhibitor + Targeted Therapy, Checkpoint Inhibitor + Other Immunotherapies, Dual Checkpoint Inhibitor Combinations

3) By Targeted Therapies: Tyrosine Kinase Inhibitors (TKIs), Monoclonal Antibodies Targeting Specific Cancer Markers

What Are The Major Trends Driving The Growth Of The Checkpoint Inhibitor Refractory Cancer Market?

Leading companies in the checkpoint inhibitor refractory cancer market are prioritizing the development of innovative products, such as dual selective inhibitors, to lessen the probability of drug resistance by targeting two crucial pathways involved in disease progression. Dual selective inhibitors are compounds designed to block two distinct biological targets or pathways simultaneously while minimizing impact on other unrelated pathways. For example, in March 2025, Pliant Therapeutics Inc., a US-based clinical-stage biopharmaceutical company, announced Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors. Pliant Therapeutics’ interim Phase 1 data for PLN-101095 in patients with immune checkpoint inhibitor–refractory advanced solid tumors demonstrated promising early activity and a manageable safety profile. At the highest tested dose of 1,000 mg twice daily combined with pembrolizumab, the trial reported a 50% objective response rate, including confirmed partial responses in patients with non-small cell lung cancer, cholangiocarcinoma, and melanoma, indicating significant tumor reductions. PLN-101095 was generally well tolerated, with most treatment-emergent adverse events being mild to moderate. The study is ongoing, with higher-dose cohorts currently enrolling and additional data expected by the end of 2025.

Which Global Market Leaders Are Shaping The Future Of The Checkpoint Inhibitor Refractory Cancer Sector?

Major companies operating in the checkpoint inhibitor refractory cancer market are Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co. Inc., AbbVie Inc., Novartis International AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline Plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Eisai Co. Ltd., Exelixis Inc., Exicure Inc., ImmunityBio Inc., ENB Therapeutics Inc., Kartos Therapeutics Inc., and Pliant Therapeutics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/checkpoint-inhibitor-refractory-cancer-global-market-report

What Regional Growth Trends Are Shaping The Checkpoint Inhibitor Refractory Cancer Market Outlook?

North America was the largest region in the checkpoint inhibitor refractory cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the checkpoint inhibitor refractory cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Checkpoint Inhibitor Refractory Cancer Market Report:

https://www.thebusinessresearchcompany.com/customise?id=27251&type=smp

Browse Through More Reports Similar to the Global Checkpoint Inhibitor Refractory Cancer Market 2025, By The Business Research Company

Green Cement Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/green-cement-global-market-report

Concrete Materials Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/concrete-materials-global-market-report

Polished Concrete Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/polished-concrete-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795